
The European Federation of Crohn’s & Ulcerative Colitis Associations (EFCCA) represents 46 national Crohn’s and Ulcerative Colitis (collectively known as Inflammatory Bowel Disease or IBD) patient associations. EFCCA is an organization of people united in their commitment to improve the life of over 10 million people living with IBD worldwide (3.4 million in Europe alone) and to give them a louder voice and more visibility.To this end, the organisation involves and empowers patients in their daily fight with IBD. IBD members are regularly invited to participate in any activity that requires direct feedback and insights, such as the METHYLOMIC project.
Involvement METHYLOMIC
EFCCA, as a partner, will play a role in launching multiple communication actions to boost the interest of patients and stimulate preparedness to participate by assessing and discussing research proposals and protocol and patient information form (PIF) from a patient perspective. EFCCA will also promote the research in patients with inflammatory bowel disease through the patient organizations in the countries where the research is taking place and announce the project results. The project will run for four years, and the kick-off meeting was on 18 January 2023 in Amsterdam.
Patient organizations
The clinical trial, named OMICROHN, will be carried out to assess the effectiveness of the rapid diagnostic test in predicting which treatment is most likely to be effective in Crohn’s Disease (CD) patients. The trial will enroll 378 Crohn’s Disease patients from the following 6 countries: Italy, Belgium, United Kingdom, Slovenia, Netherlands, and Hungary, via over 50 clinical sites.
The below patient organizations are active in the 6 countries where the OMICROHN trial will be carried out.